Eddielkh
2021-12-20
Comment and like plz thanks
Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":693870009,"tweetId":"693870009","gmtCreate":1640007749731,"gmtModify":1640007750139,"author":{"id":3559888727257208,"idStr":"3559888727257208","authorId":3559888727257208,"authorIdStr":"3559888727257208","name":"Eddielkh","avatar":"https://static.tigerbbs.com/8f02256556ae7f7c1567be3df06b2567","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":33,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Comment and like plz thanks</p></body></html>","htmlText":"<html><head></head><body><p>Comment and like plz thanks</p></body></html>","text":"Comment and like plz thanks","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693870009","repostId":2192184609,"repostType":4,"repost":{"id":"2192184609","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640007420,"share":"https://www.laohu8.com/m/news/2192184609?lang=&edition=full","pubTime":"2021-12-20 21:37","market":"us","language":"en","title":"Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year","url":"https://stock-news.laohu8.com/highlight/detail?id=2192184609","media":"Dow Jones","summary":"Biogen Inc. $(BIIB)$ said Monday it will reduce the price of its Alzheimer's drug aduhelm by 50% sta","content":"<p>Biogen Inc. <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> said Monday it will reduce the price of its Alzheimer's drug aduhelm by 50% starting Jan. 1 in an effort to get it to more patients with early signs of the disease. </p>\n<p>\"For a patient of average weight (74 kg), the yearly cost at the maintenance dose (10 mg/kg) will be $28,200,\" the company said in a statement. </p>\n<p>It said the decision comes after feedback from stakeholders with too many people unable to access the treatment because of its high cost. </p>\n<p>\"Biogen is taking this action with the goal of lowering out-of-pocket expenses for patients and reducing the potential financial implications for the U.S. healthcare system,\" said the statement. </p>\n<p>The company is expecting that with insurance coverage and access to specialized centers, about 50,000 patients may start taking aduhelm in 2022. </p>\n<p>The company is also planning to cut costs in 2022 to offset a hit to revenue from the continued entry of generics to the multiple sclerosis market and the delayed uptake of aduhelm, which was approved by the U.S. Food and Drug Administration last year despite some shaky trials. </p>\n<p>The approval was controversial and Biogen in July requested a narrower indication -- the initial approval was for all people with the disease. Several members of the FDA's advisory committee that voted against the agency approving aduhelm quit in response, and acting FDA commissioner Janet Woodcock in July announced a federal investigation into the approval process. </p>\n<p>Biogen shares jumped 3% premarket on the news, but are down 3% in the year through Friday, while the SPDR S&P Biotech ETF <a href=\"https://laohu8.com/S/XBI\">$(XBI)$</a> has fallen 18% and the S&P 500 has gained 23%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen to lower price of Alzheimer's drug aduhlem by 50% starting Jan. 1 to about $28,200 a year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 21:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biogen Inc. <a href=\"https://laohu8.com/S/BIIB\">$(BIIB)$</a> said Monday it will reduce the price of its Alzheimer's drug aduhelm by 50% starting Jan. 1 in an effort to get it to more patients with early signs of the disease. </p>\n<p>\"For a patient of average weight (74 kg), the yearly cost at the maintenance dose (10 mg/kg) will be $28,200,\" the company said in a statement. </p>\n<p>It said the decision comes after feedback from stakeholders with too many people unable to access the treatment because of its high cost. </p>\n<p>\"Biogen is taking this action with the goal of lowering out-of-pocket expenses for patients and reducing the potential financial implications for the U.S. healthcare system,\" said the statement. </p>\n<p>The company is expecting that with insurance coverage and access to specialized centers, about 50,000 patients may start taking aduhelm in 2022. </p>\n<p>The company is also planning to cut costs in 2022 to offset a hit to revenue from the continued entry of generics to the multiple sclerosis market and the delayed uptake of aduhelm, which was approved by the U.S. Food and Drug Administration last year despite some shaky trials. </p>\n<p>The approval was controversial and Biogen in July requested a narrower indication -- the initial approval was for all people with the disease. Several members of the FDA's advisory committee that voted against the agency approving aduhelm quit in response, and acting FDA commissioner Janet Woodcock in July announced a federal investigation into the approval process. </p>\n<p>Biogen shares jumped 3% premarket on the news, but are down 3% in the year through Friday, while the SPDR S&P Biotech ETF <a href=\"https://laohu8.com/S/XBI\">$(XBI)$</a> has fallen 18% and the S&P 500 has gained 23%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BIIB":"渤健公司","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192184609","content_text":"Biogen Inc. $(BIIB)$ said Monday it will reduce the price of its Alzheimer's drug aduhelm by 50% starting Jan. 1 in an effort to get it to more patients with early signs of the disease. \n\"For a patient of average weight (74 kg), the yearly cost at the maintenance dose (10 mg/kg) will be $28,200,\" the company said in a statement. \nIt said the decision comes after feedback from stakeholders with too many people unable to access the treatment because of its high cost. \n\"Biogen is taking this action with the goal of lowering out-of-pocket expenses for patients and reducing the potential financial implications for the U.S. healthcare system,\" said the statement. \nThe company is expecting that with insurance coverage and access to specialized centers, about 50,000 patients may start taking aduhelm in 2022. \nThe company is also planning to cut costs in 2022 to offset a hit to revenue from the continued entry of generics to the multiple sclerosis market and the delayed uptake of aduhelm, which was approved by the U.S. Food and Drug Administration last year despite some shaky trials. \nThe approval was controversial and Biogen in July requested a narrower indication -- the initial approval was for all people with the disease. Several members of the FDA's advisory committee that voted against the agency approving aduhelm quit in response, and acting FDA commissioner Janet Woodcock in July announced a federal investigation into the approval process. \nBiogen shares jumped 3% premarket on the news, but are down 3% in the year through Friday, while the SPDR S&P Biotech ETF $(XBI)$ has fallen 18% and the S&P 500 has gained 23%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":895,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":23,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/693870009"}
精彩评论